3-(N-methylsulfamoyl)propanoic acid | 933714-87-5

• 英文名称: 3-(N-methylsulfamoyl)propanoic acid
• 英文别名: 3-(N-methylsulfamoyl)propanoic acid hydrochloride；3-(Methylsulfamoyl)propanoic acid
• CAS: 933714-87-5
• 化学式: C₄H₉NO₄S
• mdl: MFCD11168961
• 分子量: 167.186
• InChiKey: MZDBJRROCIFXFX-UHFFFAOYSA-N

物化性质

• 沸点：
  349.1±44.0 °C(Predicted)
• 密度：
  1.404±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(N-methylsulfamoyl)propanoic acid 、 3-(1-(pyridin-3-ylmethyl)-1H-pyrazol-3-yl)-[1,1'-biphenyl]-4-amine 在 1-丙基磷酸酐 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以30 %的产率得到3-(N-methylsulfamoyl)-N-(3-(1-(pyridin-3-ylmethyl)-1H-pyrazol-3-yl)-[1,1'-biphenyl]-4-yl)propanamide
  参考文献：
  名称：

  [EN] 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD
  [FR] 2-PYRAZOLE ANILINES ET ANALOGUES APPARENTÉS POUR INHIBER YAP/TAZ-TEAD

  摘要：

  The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.

  公开号：

  WO2023122780A2
• 作为产物：
  描述：

  N-(2-Methoxycarbonyl)ethyl-N'-methyl-schwefelsaeurediamid 、 1,4-二氧六环 、 水 以4%的产率得到
  参考文献：
  名称：

  UNTERHALT, BERNARD;HANEWACKER, GEORG-ANDREAS, ARCH. PHARM., 321,(1988) N 10, C. 749-751

  摘要：

  DOI：

文献信息

• [EN] DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS<br/>[FR] DÉRIVÉS DE DIHYDRO-INDÈNE EN TANT QU'INHIBITEURS DE MALT1
  申请人：[en]C4X DISCOVERY LIMITED

  公开号：WO2023218203A1

  公开（公告）日：2023-11-16

  The present invention relates to compounds that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with MALT1.